Literature DB >> 16355343

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.

Anthony E Zimmermann1, Thomas Pizzoferrato, John Bedford, Anne Morris, Robert Hoffman, Gregory Braden.   

Abstract

Tenofovir therapy in patients with human immunodeficiency virus (HIV) infection has been associated with acute renal failure (ARF) and Fanconi syndrome. In the past 2 years, we diagnosed tenofovir-associated ARF in 5 HIV-infected patients who were receiving tenofovir therapy and who had classic findings of acute tubular necrosis, and we compared findings for our patients with data on 22 patients described in the literature. The mean serum creatinine level increased from 0.9 to 3.9 mg/dL, and it decreased to 1.2 mg/dL during recovery. ARF resolved in 22 of 27 patients after discontinuation of tenofovir therapy. The most common drugs given with tenofovir were ritonavir or lopinavir-ritonavir (21 of 27 patients), atazanavir (5 of 27 patients), and didanosine (9 of 27 patients). Tenofovir-associated ARF manifests as acute tubular necrosis that may not resolve with tenofovir withdrawal. Tenofovir is associated with multiple drug interactions, leading to an increased risk of ARF. Frequent monitoring of renal function is warranted for any patient receiving these combinations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16355343     DOI: 10.1086/499048

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  83 in total

Review 1.  Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.

Authors:  Douglas Krakower; Kenneth H Mayer
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

2.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 3.  Emerging reverse transcriptase inhibitors for HIV-1 infection.

Authors:  Mohammad A Rai; Sam Pannek; Carl J Fichtenbaum
Journal:  Expert Opin Emerg Drugs       Date:  2018-05-10       Impact factor: 4.191

4.  Acute renal injury in a 14-year-old with HIV/AIDS and tuberculosis.

Authors:  Kristopher R Bosse; Eric A Russell; Kudakwashe R Chikwava; Richard M Rutstein; Elizabeth Lowenthal
Journal:  Pediatr Infect Dis J       Date:  2013-09       Impact factor: 2.129

Review 5.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Authors:  Atefeh Jafari; Hossein Khalili; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2014-06-25       Impact factor: 2.953

6.  Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Authors:  Lene Ryom; Amanda Mocroft; Ole Kirk; Signe W Worm; David A Kamara; Peter Reiss; Michael Ross; Christoph A Fux; Philippe Morlat; Olivier Moranne; Colette Smith; Jens D Lundgren
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

7.  Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.

Authors:  Lloyd Mulenga; Patrick Musonda; Albert Mwango; Michael J Vinikoor; Mary-Ann Davies; Aggrey Mweemba; Alexandra Calmy; Jeffrey S Stringer; Olivia Keiser; Benjamin H Chi; Gilles Wandeler
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

Review 8.  Screening for chronic kidney disease in HIV-infected patients.

Authors:  Michelle M Estrella; Derek M Fine
Journal:  Adv Chronic Kidney Dis       Date:  2010-01       Impact factor: 3.620

Review 9.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  The nephrotoxic effects of HAART.

Authors:  Hassane Izzedine; Marianne Harris; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.